JP2024546096A - コンドロイチン硫酸プロテオグリカン(cspg4)ポリペプチドの結合剤 - Google Patents

コンドロイチン硫酸プロテオグリカン(cspg4)ポリペプチドの結合剤 Download PDF

Info

Publication number
JP2024546096A
JP2024546096A JP2024533985A JP2024533985A JP2024546096A JP 2024546096 A JP2024546096 A JP 2024546096A JP 2024533985 A JP2024533985 A JP 2024533985A JP 2024533985 A JP2024533985 A JP 2024533985A JP 2024546096 A JP2024546096 A JP 2024546096A
Authority
JP
Japan
Prior art keywords
seq
antigen
cspg4
amino acid
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024533985A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024546096A5 (cg-RX-API-DMAC7.html
Inventor
ベンジャミン マッカーシー,ジェームズ
ヤン,ジエンボー
プライス,マシュー
フェリセス,マーティン
ミラー,ジェフリー
レンヴィク,トッド
Original Assignee
リージェンツ オブ ザ ユニバーシティ オブ ミネソタ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リージェンツ オブ ザ ユニバーシティ オブ ミネソタ filed Critical リージェンツ オブ ザ ユニバーシティ オブ ミネソタ
Publication of JP2024546096A publication Critical patent/JP2024546096A/ja
Publication of JP2024546096A5 publication Critical patent/JP2024546096A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3053—Skin, nerves, brain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
JP2024533985A 2021-12-07 2022-12-07 コンドロイチン硫酸プロテオグリカン(cspg4)ポリペプチドの結合剤 Pending JP2024546096A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163286719P 2021-12-07 2021-12-07
US63/286,719 2021-12-07
PCT/US2022/052099 WO2023107538A2 (en) 2021-12-07 2022-12-07 Binders of chondroitin sulfate proteoglycan (cspg4) polypeptides

Publications (2)

Publication Number Publication Date
JP2024546096A true JP2024546096A (ja) 2024-12-17
JP2024546096A5 JP2024546096A5 (cg-RX-API-DMAC7.html) 2025-12-09

Family

ID=86731156

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024533985A Pending JP2024546096A (ja) 2021-12-07 2022-12-07 コンドロイチン硫酸プロテオグリカン(cspg4)ポリペプチドの結合剤

Country Status (4)

Country Link
US (1) US20250313648A1 (cg-RX-API-DMAC7.html)
EP (1) EP4444753A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024546096A (cg-RX-API-DMAC7.html)
WO (1) WO2023107538A2 (cg-RX-API-DMAC7.html)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012503203A (ja) * 2008-09-19 2012-02-02 ユニバーシティ オブ ピッツバーグ − オブ ザ コモンウェルス システム オブ ハイヤー エデュケイション 基底乳癌腫の診断および処置のためのcspg4に対するモノクローナル抗体
US10093745B2 (en) * 2013-05-29 2018-10-09 The Regents Of The University Of California Anti-CSPG4 fusions with interferon for the treatment of malignancy
EP3218413A4 (en) * 2014-11-12 2018-03-28 Memorial Sloan-Kettering Cancer Center Anti-chondroitin sulfate proteoglycan 4 antibodies and uses thereof
WO2016164429A1 (en) * 2015-04-06 2016-10-13 The General Hospital Corporation Anti-cspg4 chimeric antigen receptors
AU2019287676A1 (en) * 2018-06-13 2021-01-07 The General Hospital Corporation Methods and compositions for chimeric antigen receptor targeting cancer cells

Also Published As

Publication number Publication date
EP4444753A4 (en) 2026-06-24
WO2023107538A3 (en) 2023-08-03
US20250313648A1 (en) 2025-10-09
WO2023107538A2 (en) 2023-06-15
EP4444753A2 (en) 2024-10-16

Similar Documents

Publication Publication Date Title
CN113661180B (zh) Tn-MUC1嵌合抗原受体(CAR)T细胞疗法
CN112512575B (zh) 双特异性抗体组合物及其使用方法
US10479997B2 (en) Compositions and methods for diagnosis and treatment of prostate cancer
CN113164589A (zh) 用于调节单核细胞和巨噬细胞发炎表型的组合物和方法以及其免疫疗法用途
CN112673093A (zh) 靶向flt3、pd-1和/或pd-l1的免疫疗法的组合物和方法
US12415867B2 (en) Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof
CN107405362A (zh) 抗dll3嵌合抗原受体及其使用方法
CN111108124B (zh) 新型抗体以及treg消耗性抗体和免疫刺激性抗体的组合使用
KR20220152220A (ko) Cd19-지시된 키메라 항원 수용체 t 세포 조성물 및 이의 방법 및 용도
KR20230058442A (ko) 간세포성 암종에 대한 lag-3 길항제 요법
TW202321287A (zh) 特異性靶向間皮素之經工程改造之免疫細胞及其用途
KR20230058408A (ko) 암 면역 미세 환경 조절 물질 및 그에 따른 예방·진단·치료적 이용
WO2025072639A1 (en) Methods of treating cancer resistant to immune checkpoint therapy and compositions useful for the same
US20260007697A1 (en) New chimeric antigen receptor (car) cells and medical uses thereof
US20240150470A1 (en) Lym-1 and lym-2 antibody compositions and improved car constructs
US20250179170A1 (en) Use of anti-claudin-1 antibodies to increase t cell availability
US20250313648A1 (en) Binders of Chondroitin Sulfate Proteoglycan (CSPG4) Polypeptides
CN120380023A (zh) 用于癌症治疗的纳米抗体
JP2015517655A (ja) Bリンパ性悪性疾患を治療するための組成物および方法
US20240165228A1 (en) Targeted inhibition of dkk3 to sensitize tumors to immunotherapy
RU2853818C9 (ru) Способ лечения заболеваний с применением антагонистов GREMLIN1
RU2853818C1 (ru) Способ лечения заболеваний с применением антагонистов GREMLIN1
Asavasupreechar et al. SLP-76/LAT AND-gated CAR-T cells mediate highly specific and durable antitumor activity in pancreatic ductal adenocarcinoma with reduced gastric toxicity
WO2024249214A2 (en) Anti-cd24 chimeric antigen receptor, compositions and methods
HK40119904A (en) Methods of administering natural killer cells comprising an anti-human epidermal growth factor receptor 2 (her2) chimeric antigen receptor (car)

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251201

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251201